SERNA-2 is a randomized, open-label, multicenter phase II trial that analyzed the efficacy and safety of camizestrant with the various dosages of 75–300 mg administered as a monotherapy in women with ER+, HER2− previously treated advanced breast cancer in comparison with fulvestrant. This evidence concerns the gene ERBB2 and breast carcinoma.